Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.

ABSTRACT:

Background and aims

Concomitant aortic stenosis (AS) and transthyretin-associated cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of structural heart failure. Aortic valve replacement (AVR) improves prognosis in this population, but the efficacy of ATTR-specific medication remains unclear. This study aimed to investigate the prognostic implications of ATTR-specific medication in patients with dual AS-CA.

Methods

This is a multicenter, international, transatlantic registry of patients with a concomitant pathology of significant AS (moderate/severe) and ATTR-CA (ClinicalTrials.gov identifier: NCT06129331). AS severity was diagnosed by transthoracic echocardiography and ATTR-CA by myocardial uptake on bone scintigraphy and/or positive endomyocardial biopsy in

SUBMITTER: Nitsche C 

PROVIDER: S-EPMC12634099 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature